Jan 11 (Reuters) - THERANEXUS SA:‍​
* THERANEXUS ANNOUNCES ISSUANCE OF EUROPEAN PATENT COVERING ITS DRUG CANDIDATE THN102 FOR TREATMENT OF NARCOLEPSY AND PARKINSON‘S DISEASE
* ‍RESULTS ARE EXPECTED IN Q2 OF 2019​ * ‍AT END OF 2017, LAUNCHED REGULATORY ACTIVITIES REQUIRED TO START NEW PHASE II CLINICAL TRIAL FOR THN102 IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.